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The World Health Organization (WHO) developed a European Regional Action Plan (EAP) to 
fasttrack action towards the goal of eliminating viral hepatitis. Robust monitoring is essential to assess 
national programme performance. The purpose of this study was to assess the availability of selected 




Availability of data sources at EU/EEA level was assessed using two surveys distributed to 31 
EU/EEA MS in 2016. The two surveys covered (A) availability of policy documents on testing; testing 
practices and monitoring; monitoring of diagnosis and treatment initiation, and; (B) availability of data 
on mortality attributable to chronic viral hepatitis. 
 
Results 
Just over two-thirds of EU/EEA MS responded to the surveys. 86% (18/21) reported national testing 
guidance covering HBV, and 81% (17/21) covering HCV; while 33% (7/21) and 38% (8/21) of 
countries, respectively, monitored the number of tests performed. 71% (15/21) of countries monitored 
the number of chronic HBV cases diagnosed and 33% (7/21) the number of people treated. 
Corresponding figures for HCV were 48% (10/21) and 57% (12/21). 27% (6/22) of countries reported 
availability of data on mortality attributable to chronic viral hepatitis. 
 
Conclusions 
The results of this study suggest that sources of information in EU/EEA Member States to monitor the 
progress towards the EAP milestones and targets related to viral hepatitis diagnosis, cascade of care 
and attributable mortality are limited. Our analysis should raise awareness among EU/EEA policy 
makers and stimulate higher prioritisation of efforts to improve the monitoring of national viral hepatitis 
programmes. 
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Introduction 
Hepatitis B and C viruses (HBV, HCV) are associated with a large burden of disease in the EU/EEA, 
with an overall HBV prevalence of 0.9% and HCV prevalence of 1.1%, corresponding to an estimated 
4.7 and 5.6 millions of cases, respectively [1]. Population groups with higher prevalence of HBV and 
HCV infection in the EU/EEA include people who inject drugs (PWID), people in prison, persons who 
have undergone unsafe medical procedures, migrants from countries with higher prevalence, men 
who have sex with men (MSM) [1–3]. Viral hepatitis disproportionately impacts upon the most 
socioeconomically deprived populations, and contributes to health inequalities in Europe [4]. 
 
The adoption of the World Health Organization’s (WHO) Global Health Sector Strategy on viral 
hepatitis includes ambitious goals and targets to eliminate viral hepatitis as a public health threat by 
2030 [5]. The Global Strategy was followed by the development and adoption of the WHO European 
Regional Action Plan (EAP) [4,5]. Robust monitoring is essential to assess national programme 
performance, including service delivery, and to inform policy development. To guide action in this 
area, WHO has developed a comprehensive and practical monitoring and evaluation framework to 
provide support to countries in monitoring their responses to the elimination of viral hepatitis [6]. The 
framework includes indicators that can be used by countries to monitor progress towards the goals 
and targets outlined in the Global Health Sector Strategy and the EAP. It is likely that additional 
indicators specific to the region targets may also be needed to monitor progress towards all the 
interim milestones and targets defined in the EAP. The EAP proposes a number of milestones and 
targets encompassing viral hepatitis surveillance, evidence-based policy and awareness, 
immunization and prevention of mother-to-child transmission of HBV, blood safety and facility-level 
injection safety, prevention of sexual and injecting-related transmission, testing for viral hepatitis 
infection and cascade of care [4]. The purpose of this study was to assess the availability of key 
sources of data in EU/EEA Member States in relation to selected EAP milestones and targets, 
namely: testing policies and practices, viral hepatitis care cascade and chronic viral hepatitis-related 




This study assessed the availability of data on testing policies and practices, viral hepatitis care 
cascade and chronic viral hepatitis-related mortality, using two surveys of EU/EEA Member States 
(MS) [7]. Due to the need to contain the size of the survey questions, only a sub-set of EAP 
milestones and targets were covered. This sub-set was selected considering the relevance for the 
European setting and based on the available information at the time of the design of the study 
protocol, which predated the release of the WHO EAP [4]. The two surveys covered (A) availability of 
guidelines and policy documents on testing; testing practices and monitoring; monitoring of diagnosis 
and treatment initiation, and; (B) availability of data on mortality attributable to HBV/HCV. For survey 
A, ‘dedicated’ testing guidance was defined as a guidance/policy document where the primary topic 
was hepatitis, and that testing was the main, or formed a component, of it. Survey B asked countries 
whether mortality data were available, rather than specifically monitored. Both surveys were designed 
in electronic format to allow respondents to complete their answers on screen and submit responses 
by email. Surveys were distributed to the official ECDC National Focal Points for Viral Hepatitis [8], 
with up to three contacts made: a group invitation, and two individualised reminders. Surveys were 




There were 21 individual responses to survey A, and 22 individual responses to survey B. The UK 
provided two separate responses for each survey; one from England & Wales, and one from 
Scotland. Therefore, the response rate was 20 (65%) out of 31 MS for survey A, and 21 (68%) out of 
31 MS for survey B. Survey results are reported by country rather than MS, due to the different 
responses from the separate UK countries. Responses to survey A and survey B were received from 
the following MS: Belgium, Bulgaria, Croatia, Denmark, Estonia, France, Germany, Hungary, Ireland, 
Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovenia (survey B only), 
Spain, Sweden, and the UK. 
 
Testing policies and practices 
Eighteen out of 21 countries responding to survey A (86%) reported having national testing guidance 
covering HBV, of which six had dedicated HBV guidance. Seventeen (81%) had national testing 
guidance covering HCV, of which 10 had dedicated HCV guidance. Thirteen countries (62%) had 
HBV/HCV testing guidance covering PWID. Six (29%) countries had HBV testing guidance for MSM 
and four (19%) had HCV testing guidance for MSM. Eight countries (38%) reported that routine 
HBV/HCV testing was offered to all people in prison settings, whereas 12 countries (57%) offered 
testing to prisoners only on the basis of risk factors or for medical reasons. HBV/HCV testing in most 
countries (71%) was reported to be offered free at the point of use or through reimbursed user fees. 
Only four (19%) MS reported that non-reimbursed user fee were sometimes charged, but no country 
reported that this was the only means of accessing testing. 
 
Viral hepatitis cascade of care 
For HBV, seven (33%) of the responding countries monitored the numbers of tests, and 15 (71%) 
monitored the number of positive cases. Four (19%) countries reported available information on the 
estimated proportion of the chronic HBV population that have not been diagnosed, which ranged from 
45% in Scotland (2014) to 55% in France (2004). Seven countries (33%) monitored the number of 
people treated for HBV. For HCV, eight (38%) countries monitored the number of tests, and 10 (48%) 
monitored the number of positive cases. Five countries could provide the estimated proportion of the 
HCV undiagnosed fraction, which ranged from 20% in Denmark (2013) to 78% in Poland (2015). 
Twelve countries (57%) monitored the number treated for HCV. 
 
Attributable mortality 
Six of 22 (27%) countries reported availability of data on at least one indicator of HBV/HCV-
attributable mortality: of these, all six reported data available on HBV/HCV-liver cancer, and five 
(23%) each on HBV/HCV liver cirrhosis and HBV/HCV chronic liver disease. All remaining countries 
reported availability of liver-related mortality data, albeit with no information on HBV/HCV status. 




The results of this study suggest that sources of information in EU/EEA Member States to monitor the 
progress towards the EAP milestones and targets related to viral hepatitis diagnosis, cascade of care 
and attributable mortality are limited. Indeed, a third of responding countries reported conducting no 
monitoring at all on any of the areas assessed. Among those countries with available data, there was 
a focus on monitoring some elements of the care cascade (e.g. number of people diagnosed and 
treated), raising concerns over the extent of the programmatic response to viral hepatitis as 
recommended by WHO [5]. In addition, some countries indicated that they were either unable, or 
unaware if it was possible, to share data on mortality related to viral hepatitis with ECDC. 
 
In order to assess programme performance, inform national policy and report on implementation of 
the WHO strategy and the EAP, EU/EEA Member States will need to build up robust monitoring 
systems. Currently most EU/EEA Member State are able to monitor notification data on newly 
diagnosed cases of HBV and HCV. However, heterogeneity of surveillance systems, use of different 
case definitions and differences in reporting practices across the region hamper the comparability of 
such data and the quality of these data [9]. Additional sources of monitoring data should include 
regular seroprevalence and possibly sentinel surveys to determine the undiagnosed fraction, and the 
fraction of cirrhosis and hepatocellular carcinoma cases attributable to HBV/HCV, as well as the 
systematic collection of programmatic data related to testing, prevention and treatment coverage. The 
development of a standardised monitoring framework at the European level, and the mobilisation of 
political support and commitment at country level to implement it, would provide a robust and explicit 
basis for ensuring appropriate levels of awareness and resource investment in monitoring activities. 
Such an initiative could establish standard and routine processes, raise awareness, and influence 
leverage of the necessary resources, as has been the experience from the European wide monitoring 
of the Dublin Declaration on HIV that is coordinated by ECDC [10]. The resources required for 
monitoring and evaluation cost a fraction of the funding currently allocated to viral hepatitis treatments 
in European countries [11,12], and would yield several benefits, both in raising the profile of viral 
hepatitis as a significant burden of disease, and in informing policy makers on the most effective 
allocation of healthcare resources to see real progress in the WHO Global Strategy on viral hepatitis 
and EAP. 
 
One of the limitations of this study is that it may have failed to capture all available sources of relevant 
data in EU/EEA Member States as it relied on the background knowledge and expertise of the country 
respondent. Many respondents reported it challenging to complete the surveys due to the breadth of 
scope and the need to consult extensively within and between national relevant institutions. While this 
might have been a valuable exercise at national level, it may have resulted in inaccurate or partial 
responses [7]. The response rate to both surveys was moderate (approx. 70%), however there was a 
geographically representative range of responses from Northern, Southern, and Eastern Europe [7]. 
Also, only a sub-set of the WHO EAP milestones and targets were covered: for example, monitoring 
of HBV vaccine coverage, provision of needle and syringe facilities, and facility-level injection safety, 
were all excluded and might warrant a dedicated assessment.  
 
In conclusion, few EU/EEA countries appear to be ready to monitor progress towards the goals and 
targets outlined in the WHO Global Health Sector Strategy and EAP on viral hepatitis based on our 
assessment of available information. Analyses such as that presented here should raise awareness 
among EU/EEA policy makers and stimulate higher prioritisation of efforts to improve the monitoring 
of national viral hepatitis programmes. 
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